AstraZeneca: encouraging results in lymphoma

(CercleFinance.com) - AstraZeneca reports that results from a phase III trial showed that Calquence (acalabrutinib), in combination with standard chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically and clinically significant improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).


A trend was observed in favor of Calquence plus chemoimmunotherapy for the secondary endpoint of overall survival (OS). OS data were not mature at the time of this analysis, and the trial will continue to evaluate OS.

MCL is a rare and generally aggressive form of non-Hodgkin's lymphoma (NHL), often diagnosed as advanced disease.

Incorporating Calquence into the first-line treatment of mantle cell lymphoma would give many more patients the opportunity to benefit from the robust efficacy and strong safety profile we have seen with this drug, commented the trial's Principal Investigator.


Copyright (c) 2024 CercleFinance.com. All rights reserved.